Recent Posts

Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that preclinical data on Tumor Treating Fields in combination …

Read More »

FDA Grants Accelerated Approval for Opdivo Plus Yervoy for Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg …

Read More »

Phase 3 Study of Ninlaro Plus Lenalidomide and Dexamethasone Fails to Meet Primary Endpoint in Newly Diagnosed Multiple Myeloma Patients

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the results …

Read More »